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ABSTRACT
Objective: The objective of the current study is to optimize and evaluate the potential of polyethylene glycolylated (PEG) glyceride Labrasol® 
nanostructured lipid carrier (NLC) composites of methotrexate (MTX) to achieve enhanced sustained release delivery in cancer treatment.
Materials and Methods: MTX-NLC was successfully prepared by hot melt emulsification and probe sonication method for spatial and controlled 
release of this therapeutic agent.
Results: The solubility screening of MTX and lipids resulted in the selection of Monostearin as solid lipid, PEGylated glyceride Labrasol® and olive oil 
as liquid lipids for the formulation of MTX-loaded NLC composites. Particle size, zeta potential, and polydispersity index of both the composites were 
confirmed using dynamic light scattering, whereby Labrasol® MTX-NLC showed high entrapment efficiency and drug loading. A spherical particle 
shape with smooth surface of all the composites was confirmed from the scanning electron microscope and transmission electron microscopy analysis. 
Labrasol® MTX-NLC showed remarkably increased cytotoxic response, augmented cellular uptake, and low half maximal inhibitory concentration 
value in MCF-7 cells. In vitro release study confirmed that encapsulation of MTX in PEGylated glyceride Labrasol® MTX-NLC resulted in enhanced 
sustained release of MTX for a period of 48 h.
Conclusion: The present study establishes that PEGylated glyceride Labrasol® MTX-NLC can be considered as a promising anticancer delivery system, 
thereby improving antitumor efficacy of the drug.
Keywords: Methotrexate, Nanostructured lipid carrier, Polyethylene glycolylated glyceride, In vitro release, MCF-7 cells, Half maximal inhibitory 
concentration value, Cellular uptake.
INTRODUCTION
In the current scenario, cancer is one of the most leading causes of 
morbidity and mortality developing in any commonality at any point 
of time [1,2]. In addition, the productiveness of the present standard 
therapies for cancer is insignificant as the cytotoxic agents are highly 
toxic, low specificity with narrow therapeutic window and demonstrate 
short biological half-lives [3]. However, due to the origination of highly 
efficient therapeutic tools, delivery technologies and the availability 
of improved comprehension on cancer biology lead to remarkable 
enhancement of cancer survival rate [4].
Methotrexate (MTX), a folate antagonist which competitively binds to 
dihydrofolate reductase enzyme thereby hampers the growth of the cell 
and arrests the cell division cycle in G1 phase and S phase (Fig. 1). It is 
used as a chemotherapeutic agent in the treatment of different tumors 
such as osteosarcoma, breast cancer, acute lymphoblastic leukemia, and 
head, neck, and lung cancer [5]. However, MTX has restricted clinical 
implementations due to its low solubility, short biological half-life, 
dose-related cytotoxicity, and cellular efflux [6].
A classic therapeutic drug delivery system for cytotoxics must be 
formulated using the US Food and Drug Administration approved 
components and has acquired the generally recognized as safe status 
for both pharmaceutical and medicinal usage [7-9]. Over the past few 
years, extensive research has been carried out in nanotechnological 
field comprising polymers or lipids [10]. Profound research has been 
carried out on nanotechnology in the design and development of potent 
cytotoxic therapeutic cargo carriers to solve various issues related to 
solubility and bioavailability of these therapeutics. These nanoparticles 
ultimately enhance the therapeutic efficacy by accurately transporting 
the drug cargo carrying the cytotoxics to the tumors and successfully 
safeguarding the drug carrier from biological conditions [11,12]. 
Furthermore, the enhanced permeability and retention effect of the 
tumor vasculature allows these nanoparticles to passively target the 
tumor and the suppressed lymphatic filtration allows them to retain at 
the specific site [13,14].
Lipid-based nanoparticles have been used as an efficient carrier 
for therapeutics for several years [15,16]. Due to the presence 
of biodegradable and biocompatible natural ingredients, these 
nanocomposites have greatly achieved importance as feasible 
substitutes to the polymeric nanoparticles [17]. These nanoparticles 
possess unique physicochemical characteristics, for which it can be 
prepared easily with the use of melt emulsification method of the 
lipids and subsequent recrystallization, thus circumventing the usage 
of possibly harmful organic solvents which are frequently used in 
polymeric nanoparticle formulations [18,19].
Among various categories of lipid nanoparticles available, the 
nanostructured lipid carriers (NLCs) comprising mixture of both solid 
and liquid (like dispersed oils in triglycerides) lipids are considered as 
the latest or second generation of lipid-based nanoplatform [20,21]. It 
possesses increased encapsulation efficacy in comparison to the first-
generation solid lipid nanoparticles (SLNs) due to the presence of 
unstructured matrix emerged by the addition of liquid lipid to the solid 
lipid matrix which curbs the expulsion of therapeutics [22-24]. NLCs 
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have been used multiple times as carrier for cytotoxic agents to induce 
tumor-specific targeting while overcoming multidrug resistance (MDR) 
and avoiding reticuloendothelial system clearance of therapeutics, 
thereby augmenting the anticancer efficacy of NLCs at the site of 
action [25].
High lipophilicity property of MTX makes it an efficient cargo to be 
encapsulated in the NLC, thereby maintaining the stability. Due to the 
opsonization process, lipidic nanocarriers after injection get discharged 
inevitably from the bloodstream and by the mononuclear phagocytic 
system get eliminated from the blood circulation [26]. Recently, different 
efforts were made to incorporate modified glycerides with hydrophilic 
moieties as polyethylene glycol (PEG) (e.g. Labrasol®) into the NLC 
formulations and have evaluated their practicability to form lipid 
matrix structure [27]. In Labrasol® (PEG-8 caprylic/capric glycerides) 
which is caprylocaproyl macrogol-8 glycerides, the PEG moiety in this 
oily vehicle is coupled with hydrophobic molecules resulting in its 
emulsifying features [28]. It offers novel dual activity as an excipient in 
the NLC carrier, primarily as an oily component and second as the PEG-
containing substrate, thereby enhancing the biological half-life of the 
therapeutic and increasing the storage stability of nanocomposites [29]. 
Thus, the rationale of the study was to formulate MTX-loaded colloidal 
NLCs using PEGylated glyceride Labrasol® and olive oil with disclosed 
benefits, thereby increasing the solubility of the drug. Furthermore, it 
protects the drug from degradation and reduces the renal clearance, 
thereby increasing its half-life in bloodstream. In addition, it augments 
the payload of MTX in NLCs, thereby allowing the sustained release 
delivery.
The objective of the present study was to design, fabricate, and optimize 
MTX-loaded NLCs using PEG-8 caprylic/capric glyceride (Labrasol®) as 
PEGylated glyceride and olive oil as non-PEGylated liquid lipid with 
Monostearin as solid lipid using hot melt emulsification and probe 
sonication production technique to assess their superiority over SLNs 
in terms of drug encapsulation efficacy, drug release properties, and 
storage stabilities. The anticancer efficacy of the optimized MTX-loaded 
NLCs was studied on breast cancer (MCF7) cell line. Hence, the novelty 
of the current study is to formulate novel NLC composites of MTX using 
Labrasol® (a PEGylated glyceride) and olive oil, to assess their sustained 
release effect and increased antitumor property.
MATERIALS AND METHODS
Materials
MTX was received as a gift from Cipla Ltd. (Goa, India). Monostearin 
(glycerol monostearate) and Tween 80 (polyoxyethylene sorbitan 
monooleate) were procured from Thermo Fisher Scientific India Pvt. 
Ltd. (Mumbai, India). Labrasol® (PEG-8 caprylic/capric glycerides) 
was provided by Gattefosse (Saint-Priest, France) as gift sample. Olive 
oil was purchased from Bertolli (Italy). Poloxamer 188 (Pluronic F68) 
was received as gift samples from BASF (USA). All other chemicals 
and solvents used were of analytical grade. The simulated gastric fluid 
and simulated intestinal fluid were prepared by following the official 
methods as described in the United States Pharmacopoeia (XXV).
Methods
Screening of a binary mixture of solid and liquid lipid phase
Depending on the parameter such as encapsulation efficiency (EE), 
solid and liquid lipid ratios were optimized. Therefore, six ratios 
of binary mixture of solid phase (Monostearin) and liquid phase 
(Labrasol®) were selected arbitrarily (90:10, 80:20, 70:30, 60:40, 50:50, 
and 40:60). The same ratios were selected again for the screening of 
another combination of binary mixture of solid lipid (Monostearin) and 
liquid lipid (olive oil) phase.
Selection of surfactants
The concentration of surfactant was optimized by formulating NLC 
formulations using Poloxamer 188 in ascending order (1% w/w, 
2% w/w, 5% w/w, and 10% w/w) of concentration by keeping other 
variables constant. Then, the size of particles and EE were evaluated 
to determine the optimized concentration of the surfactant for the 
formulation of NLC.
Preparation of MTX-NLCs
The MTX-NLCs were formulated using hot melt emulsification and 
probe sonication technique which shows the superiority over other 
processes as it is one of the most cost-effective and less time-consuming 
processes for the production of NLC formulations [30]. Briefly, the lipid 
phase comprised Monostearin and Labrasol® along with MTX which 
were melted beyond 81°C with continuous stirring in a beaker on a 
hot plate magnetic stirrer (Tarsons Products Pvt. Ltd., Kolkata, India). 
The aqueous phase consisting of deionized water and Poloxamer 188 
was taken in another beaker and temperature was maintained similar 
to that of the above-melted lipid mixture. To the lipid phase mixture, 
heated aqueous mixture was added under continuous stirring at 
600 rpm and heated using hot plate magnetic stirrer to form a primary 
microemulsion. It was then homogenized using a homogenizer (Ultra 
Turrax® T10, IKA) at 10,000 rpm for 5 min then subjected to probe 
sonication at 2 min interval for 10 min at 75% amplitude. NLCs 
containing olive oil as liquid lipid were also formulated following the 
above procedure. The preparation method of the blank NLCs was 
similar only without MTX. Then, the hot NLC dispersion was kept at 
25°C for cooling to allow lipid solidification and to achieve the desired 
NLC composites.
Physicochemical characterization of the formulated MTX-NLCs
Evaluation of particle size (PS), polydispersity index (PDI), and zeta 
potential
By the utilization of dynamic light scattering (DLS) technology, the 
average PS, size distribution pattern, and PDI of NLCs were evaluated 
in a Zetasizer Nano ZS90 analyzer (Malvern Instruments, Malvern, UK). 
Whereas, depending on the electrophoretic mobility in the presence of 
the electric field, the zeta potential was measured. The NLCs suspension 
was then vortexed after diluting with deionized water to bypass the 
phenomena of multiple scattering, kept in polystyrene cuvettes for the 
evaluation of all the above parameters.
Determination of drug EE% and drug loading (DL%) efficiency
Both EE% and DL% of MTX in the formulated NLCs were calculated 
using ultrafiltration method [31]. MTX-NLC dispersion of 0.5 ml 
was poured into an ultrafiltration centrifuge tubes and then 
subjected to centrifugation (Remi CPR-24) at 9000 rpm for 40 min. 
Then, the amount of free MTX present in the ultrafiltrate was 
quantified spectrophotometrically at λmax 302 nm using ultraviolet/
visible (UV/VIS) spectrophotometer (JASCO V-550) using 1 cm quartz 
cells. Each experiment was carried out in triplicates.
The EE% and DL% were calculated by the following equations:
 −






Fig. 1: Molecular structure of methotrexate
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Where, Wtotal was the amount of the total MTX in NLC, Wfree was the 
amount of unencapsulated MTX remaining in ultrafiltrate, and WLipid 
was the total amount of the lipid in the NLC composite.
Fourier-transform infrared (FTIR) spectroscopy
The IR absorption analysis of pure drug (MTX), blank NLC formulation 
(without MTX), and MTX-NLC formulation (MTX loaded) were scanned 
by FTIR instrument (JASCO International Co. Ltd.; FT-IR 4200; Tokyo; 
Japan) to detect potential physical interactions. Conventional potassium 
bromide (KBr) disk or pellet method was used at 1:100 (sample: KBr) 
ratio, compressed by applying pressure in a hydraulic press. The 
scanning range for FT-IR measurement was 4000–400 cm−1 operated at 
a constant resolution of 3 cm−1.
Differential scanning calorimetry (DSC)
DSC thermal analytical technique was used to determine the 
thermodynamic property of MTX (whether crystalline or amorphous) 
in the nanoparticles. DSC analysis of MTX, blank (without drug), and 
lyophilized powders of MTX-NLC was sealed packed in an aluminum 
pan in Pyris Diamond thermogravimetry/differential thermal analysis 
(Perkin Elmer, Singapore) instrument at 10°C/min rate of heating and 
at 30–200°C temperature ranging. The total setup was carried out 
under nitrogen atmosphere (150 ml/min) protection.
Powder X-ray diffraction (PXRD)
The PXRD instrumental investigation of pure MTX powder, lyophilized blank 
NLC, and optimized MTX-NLC was carried out using a Philips Analytical 
PXRD spectrometer with Ni-filtered Cu-Kα tube source of radiation, 
operating at 40 kV tube pressure and current of 50 mA. All the samples were 
analyzed over 5°–40° at 1.3° min−1 of scanning rate at 2θ diffraction angle.
Field emission scanning electron microscopy (FESEM) for surface 
morphology characterization
The surface morphology of the MTX-NLCs was carried out using FESEM 
(JSM-6700F; Jeol, Tokyo, Japan). Briefly, freeze-dried MTX-NLCs were 
smoothly spread over a double-sided conductive carbon tape, followed 
by platinum coating. The images of the samples were then visualized 
at different magnifications with the aid FESEM at an accelerating 2 kV 
voltage [32].
Transmission electron microscopy (TEM)
TEM analysis of MTX-NLCs was carried out to observe the morphology 
of the nanocomposites. About 1 mg of the lyophilized MTX-NLC 
formulation was added to 2 ml of Milli-Q water in an Eppendorf tube, 
then vortexed and sonicated properly to prevent agglomeration. Then, 
4 μl of MTX-NLC suspension was placed on copper grids followed 
by liquid nitrogen storage until analysis. Finally, TEM images were 
recorded on a TEM system (JEOL) at 200 kV of acceleration voltage.
Lyophilization of MTX-NLCs
To evaluate the efficacy of the formulated NLCs to reconstitute on 
dehydration, this study was performed. The formulated NLCs were 
taken in beaker then kept at −30°C for 5 h. The samples were then 
lyophilized in a lyophilizer (Laboratory Freeze Dryer, Instrument India 
Ltd., Kolkata, India) at −55°C for 48 h. In the current study, comparative 
study of the effects of three different types of cryoprotectants (sucrose, 
mannitol, and lactose) in the concentration of 15% was evaluated. The 
reconstitution assay was carried out by dispersing the freeze-dried 
formulations in Milli-Q water and vortexed sufficiently for rehydration 
of the formulations before further characterization studies.
In vitro investigations
In vitro drug release study
The in vitro release of MTX from the MTX-NLC composite was 
determined in medium-like phosphate buffer (pH 7.4) by utilizing 
a vertical Franz diffusion cell with a dialysis membrane (HiMedia, 
Mumbai, India) having molecular weight cutoff range of 12,000–
14,000 kDa served as a diffusion membrane [33]. Pieces of the dialysis 
membrane were soaked in the dissolution media for 24 h before the 
experiment then tied to the diffusion cell or donor compartment. The 
receptor compartment was filled with 40 ml of dissolution medium 
being stirred at 100 rpm and temperature maintained at 37±0.5°C by 
means of thermostatically maintained water bath. MTX-NLC powder 
(100 mg) dispersed in 3 ml of the buffer solution was placed in the 
donor compartment. Aliquots (1 ml) were withdrawn periodically 
from the receptor compartment which was replaced with an equivalent 
quantity of fresh medium to maintain the sink condition and assayed 
by a UV/VIS spectrophotometer (JASCO V-550) at 302 nm. Dissolution 
experiments were carried out in triplicates.
In vitro cytotoxicity assessment
The cytotoxicity study of free MTX, MTX encapsulated NLC (MTX-
NLC) on breast cancer cell line (MCF7) was evaluated using 3-(4,5-di-
methylthiazol-2yl)-2,5-diphenyl tetrazolium bromide (MTT) assay [34]. 
The cell lines were obtained from the National Centre for Cell Science, 
Pune, India. The experiments were performed in 96-well flat bottomed 
culture plates (BD Biosciences, USA). The cells were placed in each well 
of the 96-well culture plate with a cell density of 5000 cell/well. MTT 
was dissolved in phosphate-buffered saline (PBS) at 5 mg/ml. Variable 
concentrations (0.1–25 μg/ml) of free MTX and MTX-loaded NLC were 
added to each well and incubated for 24 h. After 24 h of incubation with 
each compound, 20 μl of the MTT dye was added to each 96-well culture 
plates then kept in an incubator for 4 h at 37°C for the formation of 
formazan crystals. After incubation, the medium was discarded, then to 
the formazan crystals, 200 μl of dimethyl sulfoxide was added. The free 
MTX solution was used as untreated or control group. The absorbance 
of the soluble formazan dye was measured at 570 nm using a microplate 
reader. The percentage of viable cells was calculated using the following 
equation:
Absorbanceof the treated cells
Cell viability (%)
Absorbanceof the untreated cells
=
Cellular uptake analysis using fluorescence imaging
A lipophilic fluorescent dye coumarin 6 (C-6) was used for the analysis 
of the cellular uptake of MTX in MCF-7 cell lines [35]. MCF-7 cell lines 
were seeded at a density of 3×105 cells/well in 6-well culture plate and 
incubated overnight inside an incubator for the cell adherence. Then, 
1 μg/ml of C-6 coencapsulated olive oil MTX-NLC and Labrasol® MTX-
NLC was added to the plate and incubated for 4 h. Then, the medium 
was removed and each well was washed thrice with PBS (pH 7.4) and 
observed under an inverted fluorescence microscope (Carl Zeiss Axio 
Observer).
Stability study
The storage stability of the lyophilized MTX-NLC formulation was 
determined by studying the changes in PS and EE by storing in different 
temperatures using DLS. MTX-NLC samples were placed in amber glass 
vials which were subjected to stability studies as per ICH guidelines. 
The samples were stored at freezing temperature (2–8°C) and at room 
temperature inside a desiccator (25±2°C) for a period of 3 months. 
Samples were analyzed for their physicochemical properties after 
30 days, 60 days, and 90 days.
Statistical analysis
Statistical analysis was performed using GraphPad Prism software 
(version 5). Data were expressed as the mean ± standard deviation. 
Differences for which p<0.05 were considered as statistically significant.
RESULTS AND DISCUSSION
Effect of the binary mixture of solid and liquid phase
Solid lipids (Monostearin) to liquid lipids (Labrasol® and olive oil) ratios 
(90:10, 80:20, 70:30, 60:40, 50:50, and 40:60) were selected randomly. 
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From the results (Fig. 2a), the entrapment efficiency of both Labrasol® 
MTX-NLC and olive oil MTX-NLC was enhanced with an increase in the 
liquid lipid amount. However, when the ratio of solid and liquid lipid 
was same, there was a sharp decline in the entrapment efficiency. From 
the groups with low liquid lipid when stored at 4°C, there was expulsion 
of drug from the NLC composites. Therefore, solid lipid to liquid lipid 
in the ratio (60:40) was selected as it showed the highest entrapment 
efficiency due to high lipophilic nature of nanocarrier matrices with 
no drug expulsion than other groups which could be attributed to the 
imperfect crystalline arrangement of NLC composite [36].
Effect of surfactant concentration on PS and entrapment efficiency
Surfactant plays an important role in the stabilization of NLC 
composites by reducing the interfacial tension between the dispersed 
and continuous phase, thereby avoiding coalescence of particles 
and agglomeration [37]. The NLC formulations were prepared using 
Poloxamer 188 as surfactants. Poloxamer 188 is a difunctional triblock 
copolymer surfactant with amphiphilic properties and composed of a 
hydrophobic block in between two hydrophilic polymer blocks. This 
property of Poloxamer 188 helps in coating lipophilic nanoparticles and 
gets adsorbed onto the surface of the NLC composites, thus providing a 
steric stabilization effect [38]. The effect of the increasing concentration 
of Poloxamer 188 (1–10% w/w) on PS is illustrated in Fig. 2b. The NLC 
composites stabilized with 1% w/w Poloxamer 188 showed inefficient 
stabilization of the formulation. Due to which, the concentration of 
Poloxamer 188 was increased to 2% w/w which showed reduction 
in PS, low particle growth was observed in comparison to other 
concentrations. An increase in surfactant concentration results in 
thicker coating of NLCs which acts as stronger steric barrier avoiding 
aggregation and resulting in reduced PS. However, when the 
concentration of Poloxamer 188 was further enhanced, it resulted 
in the production of foam. Therefore, 2% w/w of the surfactant was 
selected as the optimum concentration for the production of NLCs.
Physicochemical characterization of the formulated NLCs
PS, PDI, and zeta potential of optimized NLC
When the NLCs were assessed by PS analyzer, it showed average PS of 
112.1±5.6 for blank NLC (Fig. 3Aa), 130.2±4.41 for olive oil MTX-NLC 
(Fig. 3Ab), and 199.6±1.7 for Labrasol® MTX-NLC (Fig. 3Ac) with their 
PDI of 0.15±0.02, 0.21±0.04, and 0.24±0.01, respectively. The increase 
in PS and PDI in case of Labrasol® MTX-NLC in comparison to olive oil 
MTX-NLC may be attributed due to the presence of PEG moieties in 
Labrasol® which could be extended to the particle surface, leading to 
increase in particle growth or PS [39]. Surface charge or zeta potential 
of all the formulations was observed as negative, −18.4±4.8 mV (blank 
NLC), −24.7±22 mV (olive oil MTX NLC), and −28.5±77 mV (Labrasol® 
MTX NLC). The diminished zeta potential of Labrasol® MTX-NLC may 
be attributed due to the presence of PEG chains of  Labrasol® covering 
the particle surfaces.
Drug EE% and DL%
The EE% of MTX into formulated NLCs was found equal to be 95.48±0.013 
and 97.25±0.024 and DL% was 9.47±0.027 and 18.48±0.012 for olive 
oil MTX-NLC and Labrasol® MTX-NLC, respectively, which confirms 
enhanced solubility of drug in the lipid matrices irrespective of the oil-
type present (p<0.05) [40].
FTIR spectroscopy
The FTIR spectra of pure MTX, blank formulation (blank), and MTX-NLC 
(Fig. 3B) were quite similar to each other. This shows that there was no 
significant interaction between MTX and other excipients used in the 
formulation. FTIR spectrum of pure MTX was showed characteristic peak 
at 1446 cm−1, 13384 cm−1, and 2936 cm−1 [41]. MTX spectrum showing 
peak at 1645 cm−1 indicates the presence of C=C stretching vibration. In 
terms ofthe interaction of MTX with excipients, no tangible shift in these 
four peaks was found indicating the absence of any interaction.
DSC
The DSC curve of pure MTX (Fig. 3C) showed a sharp endothermic 
peak appearing at about 195°C which corresponds to its melting point 
and indicating its crystalline nature. The DSC spectra of the MTX-NLC 
formulation displayed a blunt endotherm at about 180–200°C which 
may be to the change of MTX from crystalline to amorphous form 
resulting in enhancement of the dissolution profile. DSC characteristic 
peaks of other two formulations displayed slight differences in the 
endothermic peak of MTX resulting in no significant physicochemical 
interaction between MTX and other excipients. The phenomenon of 
slight shift of MTX in MTX-NLC formulation may be explained as the 
formation of nanoparticles [42].
PXRD
The PXRD patterns of the pure MTX, blank formulation, and MTX-NLC 
are shown in Fig. 3D. Pure MTX showed diffraction pattern at 11.35°, 
12.74°, 14.3°, 17.5°, 19.42°, 23.01°, and 26.93° over a diffraction angle 
of 2θ indicating a crystalline nature [35], whereas XRD spectra of blank 
NLC showed loss of peaks and diffused peaks at 19.25°, 21.2°, and 
23.3° which indicate the peaks of excipients used. XRD spectra of MTX-
NLC showed peaks at 19.35°, 21.5°, and 23.5° resulting in shifting of 
peaks, which suggest the conversion of pure MTX from crystalline to an 
amorphous state and nearly complete entrapment of the pure MTX in 
NLC composites which were consistent with the DSC studies.
FESEM study
FESEM images of lyophilized Labrasol® MTX-NLC and olive oil MTX-NLC 
at different magnifications, namely ×30,000 and ×70,000 were carried 
out to determine the shape and size of the NLC composites. The images 
of olive oil MTX-NLC at 30,000×magnification (Fig. 4a) and Labrasol® 
MTX-NLC when captured at ×70,000 magnification showed that the 
Fig. 2: (a) Effect of different ratios of solid lipid (Monostearin) and liquid lipids (Labrasol® and olive oil) on the entrapment efficiency of 
the nanostructured lipid carriers (NLCs). (b) Effect of Poloxamer 188 concentration on the particle size of NLCs. Data are represented as 
mean ± standard deviation (n=3)
a b
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NLCs were in nanosize range (100–300 nm) with smooth and distinct 
spherical structure (Fig. 4b). The average PS of the MTX-NLC correlated 
well to the values obtained by DLS.
TEM study
The TEM images obtained were carried out to observe the morphology 
of the internal structure of the NLCs. MTX-NLCs in both the images 
showed spherical in shape. TEM image of Labrasol® MTX-NLC (Fig. 5b) 
showed PS larger than that of olive oil MTX-NLC (Fig. 5a), which may 
be due to the presence of PEG chains present in Labrasol®. For passive 
Fig. 6: In vitro drug release profiles of fresh olive oil methotrexate 
(MTX)-nanostructured lipid carrier (NLC), fresh Labrasol® 
MTX-NLC, lyophilized olive oil MTX-NLC, and lyophilized Labrasol® 
MTX-NLC in phosphate buffer pH 7.4. Data are expressed in mean 
± standard deviation (n=3)
Fig. 3: (A) Size distribution curve of (a) blank-nanostructured 
lipid carrier (NLC), (b) olive oil metho
trexate (MTX)–NLC, (c) Labrasol® MTX-NLC. (B) Fourier-
transform infrared spectra, (C) differential scanning calorimetry 
thermograms, and (D) powder X-ray diffraction pattern of 
(a) MTX, (b) blank formulation, (c) MTX-NLC formulation
DC
BA
Fig. 4: Field emission scanning electron microscopy images 
of (a) olive oil methotrexate (MTX)-nanostructured lipid 
carrier (NLC) at 30,000×magnification (b) Labrasol® MTX-NLC 
at 70,000× magnification
ba
Fig. 5: Transmission electron microscopy images of (a) olive 
oil methotrexate (MTX)-nanostructured lipid carrier (NLC) 
(b) Labrasol® MTX-NLC
ba
Table 1: PS and PDI of blank NLCs, olive oil NLCs, and Labrasol® NLCs before and after lyophilization using sucrose, mannitol, and lactose 
as cryoprotectants
Formulations Cryoprotectants (15% w/w) PS (nm)±SD PDI±SD
Blank NLC
Fresh Nil 112.1±5.6 0.15±0.02




Fresh Nil 130.2±4.41 0.21±0.04




Fresh Nil 199.6±1.7 0.24±0.01
Lyophilized Sucrose 214.16±49.2 0.28±0.008
Mannitol 463.16±99.4 0.46±0.003
Lactose 847.22±301.02 0.757±0.004
All determinations were performed in triplicate and values are expressed as mean±SD, n=3. SD: Standard deviation, PDI: Polydispersity index, NLC: Nanostructured lipid 
carrier, MTX: Methotrexate, PS: Particle size
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cancer targeting, PS ranging from 100 to 300 nm is considered to be 
suitable as these particles can easily penetrate into the intracellular 
space [43]. Due to the presence of PEG chains at the surface of the 
nanoparticles, the outer layer of Labrasol® MTX-NLC is slightly lighter 
in color in comparison to olive oil MTX-NLC [44]. Both the TEM results 
showed PS within the desired range (100–200 nm).
Lyophilization of MTX-NLCs
One parameter of producing optimized NLCs is to maintaining a 
stabilized internal structure of the NLC formulation on storage. 
In general, lyophilized compositions show less aggregations 
of nanoparticles resulting in more stabilized nanocomposites 
in comparison to liquid formulations [45]. Different types of 
cryoprotectants (sucrose, lactose, and mannitol) in the concentration 
of 15% w/w were evaluated. Initially, 7% w/w concentration 
was tried which resulted in high PS and PDI. The concentration of 
cryoprotectants in the range of 10–30% usually produces stable 
formulations [46]; hence, 15% w/w concentration of cryoprotectants 
was selected. From the results in Table 1, when 15% w/w sucrose was 
used, there was slight increase in the PS and PDI in comparison to the 
fresh formulation which may be due to the disaccharides which reduce 
the osmotic activity of water and crystallization favoring an amorphous 
state. Disaccharide lactose lyophilized formulations cause aggregation 
of particles resulting in enlargement of PS and size distribution [47]. 
Mannitol lyophilized samples resulted in enlargement in PS and an 
increase in PDI. Formulations coated with 15% w/w sucrose showed 
homogeneous PS and improved redispersibility which may be due to 
the ability of sucrose to interacts with polar groups of lipids, and help in 
stabilizing the membranes after freeze-drying removed by the process 
of sublimation and therefore used for further lyophilization process.
In vitro investigations
In vitro drug release study
The in vitro release profiles of MTX from freshly prepared and 
lyophilized Labrasol® MTX-NLC and olive oil MTX-NLC are presented in 
Fig. 6. Release of MTX from the MTX-NLC formulation showed biphasic 
pattern, burst or fast release at the beginning for a period of about 
4–8 h, and sustained release for a period of 48 h. The preliminary burst 
release of MTX from the MTX-NLC is due to the diffusion of the drug 
molecules located on the surface of the nanocomposites [48]. It was 
observed that the cumulative percentage release of all the formulations 
was significantly different at 8 h (p<0.05). Sustained release of MTX 
occurs due to the lipophilic nature of the mixture of solid and liquid 
lipids which acts as a reservoir for the NLCs. The cumulative percentage 
release from the freshly formulated Labrasol® MTX-NLC (66.45%) was 
less than that of freshly formulated olive oil MTX-NLC (94.26%). This 
may be attributed to the presence of the PEG moieties of Labrasol® at 
the surface of the NLCs causing a barrier for the diffusion of therapeutic 
moiety to the medium [49]. The lyophilized form of Labrasol® MTX-
NLC showed an incremental rise in the cumulative percentage release 
of MTX (79.46%), whereas the lyophilized form of non-PEGylated olive 
oil MTX-NLC showed decrease in their cumulative release (92.68%) in 
comparison to their fresh formulations, respectively. The enhancement 
Fig. 7: (a) Cell cytotoxicity effects analysis of free methotrexate (MTX) solution, olive oil MTX-nanostructured lipid carrier (NLC), and 
Labrasol® MTX-NLC on MCF-7 cells at 24 h using 3-(4,5-di-methylthiazol-2yl)-2,5-diphenyl tetrazolium bromide assay method. (b) Half 
maximal inhibitory concentration of free MTX solution, olive oil MTX-NLC, and Labrasol® MTX-NLC formulations in MCF-7 cells. Data are 
expressed in mean ± standard deviation (n=3)
ba
Fig. 8: Cellular uptake analysis of MCF-7 cells incubated for 4 h 
with (a) blank coumarin-6 (C-6), (b) coumarin-6 (C-6) olive 
oil methotrexate (MTX)-nanostructured lipid carrier (NLC), 
and (c) coumarin-6 (C-6) Labrasol® MTX-NLC using inverted 
fluorescence microscopy imaging. In all the images, (I) corresponds 
to the images produced in green fluorescence channel, (II) 
represents the MCF-7 cells differential interface contrast images, 
(III) is the superimposition of (I) and (II), and (IV) and (V) 
correspond to the horizontal line series determination of the white 
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of release from the lyophilized Labrasol® MTX-NLC might be due to 
the formation of hydrogen bond by the cryoprotectant and the PEG 
moieties, thereby enhancing the release rate by enabling the surface 
of the nanoparticle to come in contact with surrounding dissolution 
medium [45].
In vitro cytotoxicity assessment
The cytotoxicity study of free MTX solution, olive oil MTX-NLC, and 
Labrasol® MTX-NLC formulations was carried out by MTT assay against 
MCF-7 breast cancer cells (Fig. 7). As observed in Fig. 7a, Labrasol® 
MTX-NLC showed highest cytotoxic response in comparison to olive 
oil MTX-NLC and free MTX solution. All the formulations showed dose-
dependent inhibition effect. As the concentration of MTX was increased, 
the cytotoxicity was enhanced accordingly in all the cases [50]. 
Maximum number of cell death was observed in the concentration of 
7 μg/ml due to the accumulation of sufficient amount of drug. The half 
maximal inhibitory concentration (Fig. 7b) value of Labrasol® MTX-NLC 
was 6.71 μg/ml compared to free MTX solution and olive oil MTX-NLC 
which was found to be 12.63 μg/ml and 9.45 μg/ml, respectively. These 
results show that Labrasol® MTX-NLC showed a significant higher 
cytotoxic effect in comparison to free MTX solution and olive oil MTX-
NLC by inhibiting the P-glycoprotein receptors and preventing the 
efflux of MTX from the cells (p<0.05). This leads to the internalization 
of MTX in the nuclei of the tumor cells and causing increased cytotoxic 
effect. These results also confirm that loading MTX into Labrasol® NLC 
can synergize the cytotoxic efficacy, thereby augmenting its anticancer 
effect.
Cellular uptake analysis using fluorescence imaging
The aim of cellular uptake analysis using a fluorescent dye is to know 
the cellular uptake efficacy of the NLCs into the cells. Microscopic 
images (Fig. 8) of MCF-7 cells were incubated for 4 h with blank C-6, 
C-6 olive oil MTX-NLC, and C-6 Labrasol® MTX-NLC. In comparison to 
the blank C-6, both C-6 olive oil MTX-NLC and C-6 Labrasol® MTX-NLC 
showed significantly high fluorescence intensity proving higher uptake 
and internalization of nanocarriers inside the cytoplasm of the MCF-
7 cells. The cellular uptake of NLCs by endocytosis leading to increased 
intensity of fluorescence also states that MTX will be effectively 
released from the NLCs in the cellular environment at the desired site 
of action [51].
Stability study
In the stability study, irrespective of the type of glyceride presents in 
the NLC formulations which were stored at freezing temperature and 
room temperature for 90 days showed minimal variation in PS and 
entrapment efficiency, thereby maintaining its loose and homogeneous 
appearance (p<0.05) (Fig. 9). However, after 90 days, increase in PS 
was more prominent at room temperature than in refrigerated storage 
conditions. The change in PS was within the acceptable limit of PS for 
cytotoxics. Therefore, this result suggests that the formulated NLCs 
were more stable in refrigerated storage temperature than at room 
temperature to provide an extended half-life period.
CONCLUSION
In this study, NLCs were formulated using two types of liquid lipids; 
Labrasol® (PEGylated glyceride) and olive oil (non-PEG lipid) and 
Monostearin as solid lipid to encapsulate MTX into the formulation. 
Results obtained from this research work clearly demonstrate 
that Labrasol® containing NLC composite showed larger PS and 
substantially provides highest entrapment efficiency with significantly 
sustained drug release of MTX (p<0.05) from NLCs in pH 7.4 phosphate 
buffer over 48 h as compared to PEG free olive oil NLC. Furthermore, 
the formulations were lyophilized using 15% cryoprotectants to 
improve the stability of the nanocomposites. Results also confirm that 
Labrasol® MTX-NLC showed the highest cytotoxic response along with 
prominent cellular uptake. Stability studies confirmed that there was 
no degradation of nanocomposites on storage at refrigerated and room 
temperature. Therefore, we conclude that loading of MTX into novel 
PEGylated glyceride Labrasol® NLC composites can be considered 
as a promising novel strategy for the delivery of MTX against cancer. 
Fig. 9: (i) Particle size (nm) and (ii) drug entrapment efficiency (%) of (a) olive oil methotrexate (MTX)-nanostructured lipid carrier 
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However, these findings are preliminary, future investigations will be 
on in vivo study of these formulations using animal model.
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